|
1) Hosoya M, Mori S, Tomoda A, et al. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephaliteis. Antimicrob Agents Chemother. 2004; 48: 4631-5
|
|
|
|
2) Tomoda A, Nomura K, Shiraishi, et al. Trial of intraventricular ribavirin therapy for subacute sclerosing panencephalitis. Brain Dev. 2003; 25: 514-7
|
|
|
|
|
3) Hotta H, et al. Full-length sequence analysis of subacute sclerosing panencephalitis (SSPE) virus, a mutation of measles vius, isolated from brain tissues of a patient shortly after onset of SSPE. Microbiol Immunol. 2006; 50: 525-34
|
|
|
|
|
|
4) Inoue T, et al. Contribution of the interleukin 4 gene to susceptibility to subacute sclerosing panencephalitis. Arch Neurol. 2002; 59: 822-7
|
|
|
|
|
|
5) Torisu H, et al. Functional MxA promoter polymorphism associated with subacute sclerosing panencephalitis. Neurology. 2004; 62: 457-60
|
|
|
|
|